The American health-care industry’s pivot to personalized medicine has attracted the interest of an unlikely group of companies — government contractors.
As health-care providers explore this new model of treatment, which involves the study of the human genome to provide personalized care, they face a problem with which many in government are familiar: analyzing an overwhelming amount of data. Read more.
Study at a glanceInova’s incidental lung nodule program has shown a 76% reduction in time…
Catherine Wymer, PharmD, is a senior clinical pharmacist at Inova 360° Concierge Medicine. As a…
Multidisciplinary pulmonary expertise supports diagnostic evaluation, treatment planning and longitudinal care Advanced lung disease and…
Heart failure is a major focus for Inova Schar Heart and Vascular’s care transformation efforts.…
TETON pivotal studies meet primary end point In two landmark phase 3 trials, nebulized Tyvaso®…
Leesburg, VA — Inova Blood Donor Services (IBDS) invites the Loudoun County community to roll…